- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
292 B. Ramlawi et al.
3.3. Role of metabolism and autoregulation
The ability of a vascular bed to adjust its tone, in order to maintain a constant flow during changes in perfusion pressure is termed autoregulation.21 This process is most effective in the coronary circulation when pressure is between 40 and 160 mmHg. Since the range of pressures over which autoregulation can be observed is different for the subendocardium, as compared to the subepicardium, flow will begin to decrease at pressures < 70–75 mmHg in the subendocardium, as compared to significantly lower pressures in the superficial layers of the myocardium.22 Clinically, systemic arterial hypertension affects the range over which autoregulation occurs in the subendocardium such that flow will begin to decline at even higher pressures. Such a change in subendocardial perfusion pressure in the setting of hypertrophic myocardium increases the likelihood of subendocardial ischemia.
During both autoregulation and metabolic regulation, the predominant changes in vasomotor tone occur in vessels <100 µm in diameter. The rate of oxygen consumption in the myocardium is closely related to myocardial perfusion via coronary microvascular tone. As the myocardial oxygen requirements increase, coronary flow rises in response. Mostly, this is due to the fact that the ability of the myocardium to extract additional oxygen to meet increased demand is limited since myocardial oxygen extraction is near maximum even under resting conditions.
3.4. Flow-induced dilation
Flow-induced dilation is a ubiquitous phenomenon of blood vessels in various organs and animals, including humans.2,23,24 Flow-induced dilation is considered to play important physiological roles as follows: first, to protect the vessel wall against friction-induced injury; second, to prevent the vascular steal phenomenon by dilating upstream vessels in the case of focal hyperemia; third, to reduce the heterogeneity of the coronary flow distribution; and fourth, to buffer the pressure distribution; in the face of rapid pressure changes.
Flow is sensed by endothelial cells through unidentified mechanoreceptors. In contrast to the myogenic response, the endothelium is
Regulation of Coronary Vascular Tone and Microvascular Physiology |
293 |
required for flow-induced dilation, and a study using excised arterioles demonstrated that NO is exclusively responsible for the flow-induced dilation in porcine coronary microvessels, whereas Jimenez et al. have shown that prostanoids are also involved in flow mediated microvascular dilation in porcine coronary arterioles.25,26 Since porcine coronary microvessels were used in both studies, differences in animal age, vessel sizes, or experimental setup can explain the discrepancy. Possible flow-induced arteriolar dilation mechanism is summarized in Fig. 8.
Autoregulation is mediated by the actions of several factors such as NO, EDHF and adenosine. Removal of a particular factor does not prevent autoregulation as the other factors seem to overtake its function. Adenosine and hydrogen peroxide also cause hyperpolarization
Fig. 8. Possible signal transduction pathway for the flow-induced arteriolar dilation, which is mediated by mechanotransduction via actin stress fibers, and the subsequent activation of the focal adhesion kinase and eNOS phosphorylation. FAK, focal adhesion kinase; sGC, soluble guanylyl cyclase. (Adapted from Ref. 2.)
294 B. Ramlawi et al.
of vascular smooth muscle. Due to the work of Dunker et al. as well as others, we now know that several factors work together to influence metabolic regulation and autoregulation leading to adequate regulation of coronary vascular tone despite interruption of any one particular pathway.21
3.5. Neurohumoral influence on microcirculation
The coronary arterial system is densely innervated with the sympathetic and parasympathetic nervous systems.27 Neurotransmitters released from nervous tissues and a wide variety of humoral substances significantly affect the microvascular tone. Table 1 summarizes these endogenous substances and their microvascular responses. The effect of neurohumoral factors on coronary microvascular tone, in addition to myogenic, flow-induced, and local metabolic controls all participate in determining the coronary vascular resistance necessary for oxygen and nutrition supply to the myocardium (Fig. 4).
The role of the autonomic sympathetic and parasympathetic nervous systems is important in regulation of coronary perfusion. In vivo, the vascular response to sympathetic stimulation is mediated by both α- adrenergic and β-adrenergic receptors. In the coronary circulation, the predominant receptor subtype seems to be the β-adrenergic receptor.28 For example, direct sympathetic nerve stimulation stimulates coronary vasodilation and an increase in coronary flow occurs. If β- adrenergic antagonists are administered, a transient vasoconstriction can be observed.28 When coronary microvessels are studied in vitro, α-adrenergic stimulation has minimal contractile effects. When selective α2-adrenergic stimulation is applied using pharmacological stimuli, there is rather potent vasodilation of all sized coronary microvessels, predominantly due to a release of endothelium-derived nitric oxide (NO•). β-adrenergic stimulation produces a potent relaxation of all coronary arteries, but especially small resistance vessels.28 Also, β2- adrenergic receptor subtype predominates in vessels less than 10 µm in diameter in in vitro studies, whereas a mixed β1 or β2-adrenergic receptor population controls vascular resistance in in vivo studies.28 On the other hand, larger coronary vessels are regulated by a mixed
Regulation of Coronary Vascular Tone and Microvascular Physiology |
295 |
Table 1. Heterogeneous coronary arterial microvascular responses in vivo to endogenous substances.
|
|
Small |
Large |
|
Agonist |
Materials |
microvesssels |
microvessels† |
Ref. no(s). |
Acetylcholine |
Dog, Cat |
Dilation |
Dilation |
2, 29 |
C1 Stimulation |
Dog |
No change |
Constriction |
10 |
(normal |
|
|
|
|
pressure) |
|
|
|
|
α1 Stimulation |
Dog |
Constriction |
Constriction |
10 |
(low pressure) |
|
|
|
|
α2 Stimulation |
Dog |
No change |
No change |
10 |
(normal |
|
|
|
|
pressure) |
|
|
|
|
α2 Stimulation |
Dog |
Constriction |
No change |
10 |
(low pressure) |
|
|
|
|
NPY |
Dog |
Constriction |
Constriction |
74 |
CGRP |
Dog |
No change |
Dilation |
75 |
Adenosine |
Dog |
Dilation |
No change |
76 |
ET-1 |
Dog |
Constriction |
Constriction |
77 |
(suffusion) |
|
|
|
|
ET-1 |
Dog |
Dilation |
No change |
77 |
(intracoronary) |
|
|
|
|
5-HT |
Cat |
Dilation |
Constriction |
47 |
Vasopressin |
Cat |
Constriction |
Dilation |
47 |
Arterial coronary microvessels < 100–150 µm.
†Arterial coronary microvessels > 100–150 µm. Source: Adapted from Ref. 2.
β1- and β2-adrenoceptor subtype population. Activation of cholinergic receptors by either vagal stimulation or the infusion of acetylcholine produces uniform vasodilation of coronary vessels.29 This vasodilation is predominantly mediated by endothelium-derived NO•, although release of EDHF,30 and the release of prostaglandin substances may also contribute.31 The coronary flow increase by vagal stimulation can be blunted by a metabolically-mediated flow decrease caused by a decrease in the heart rate and myocardial contractility.32
